Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

New Alzheimer’s experimental treatment gives researchers optimism

Staff Writer
Staff Writer 5 years ago
Updated 2019/06/28 at 7:27 PM
Share
SHARE

In the U.S., more than five million people live with cognitive impairment associated with Alzheimer’s, with that number reaching 10 million in a worldwide setting, according to statistics by the Alzheimer’s Association.

Despite the growing number of cases each year, researchers have failed to establish contentment in a treatment that could particularly help reduce or reverse symptoms of the neurodegenerative disease. That is, until now.

Researchers are turning to BAN2401, an experimental drug able to antagonize the protein fragment beta-amyloid, instrumental in the development of cognitive deficits caused by the disease.

In a clinical trial, researchers found that the new experimental drug, manufactured by Biogen and Eisai, had significantly improved cognitive decline in patients by up to 30 percent when administered at the highest dose following 18 months of tests.

Compared to a placebo, BAN2401 demonstrated efficacy in improving cognition, while reducing new and existing beta-amyloid clusters by up to 70 percent. Researchers say the treatment reached a 20 percent slowing rate of Alzheimer’s progression in a period of 12 months, faster than the fixated goal set at 18 months.

Lynn Kramer, the chief medical officer at Eisai, dubbed the test a success in a media briefing. “We think this result is really the first of its kind, robust enough to approach regulatory authorities to discuss next steps.”

The findings provide optimism given the notion of previously failed clinical trials targetting amyloid plagues. Moreover, Biogen has announced the testing of another experimental treatment, this one named “aducanumab.” It’s expected to enter more clinical trials by 2020. Researchers remain hopeful that further testing of the amyloid hypothesis may bring about the world’s first effective treatment for the neurodegenerative disease.

“What we see is the amyloid hypothesis remains something that needs to continue to be tested,” said Maria Carrillo, the chief scientific officer of the Alzheimer’s Association.

You Might Also Like

Cognitive disorders may develop due to molecular overreaction to ribosome stalling

Researchers have uncovered hints as to why immune cells appear to cause brain damage

Researchers use AI to generate video from brain activity

People are more creative upon awakening from the earliest stage of sleep: new study

Memory loss associated with Alzheimer’s may be mitigated through deep sleep

TAGGED: Alzheimer's disease, amyloid, dementia, Featured, neurodegenerative diseases
Staff Writer July 26, 2018
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article Scientists uncover new connection between smell and memory
Next Article Warming temperatures linked to increase in suicide rates

Recommended

Clinical

Cognitive disorders may develop due to molecular overreaction to ribosome stalling

2 Min Read
Clinical

Researchers have uncovered hints as to why immune cells appear to cause brain damage

1 Min Read
Clinical

Researchers use AI to generate video from brain activity

2 Min Read
Clinical

People are more creative upon awakening from the earliest stage of sleep: new study

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?